Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common cause of cancer-specific death in men, according to the American Cancer Society. Approximately 70% of bladder tumors present as non-muscle invasive (NMI) disease and 10%-20% will progress to muscle invasion.
A 10-year follow-up study of patients with high-risk bladder cancer shows that mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) have similar effects on disease progression, need for subsequent treatment, and survival.
A principal reason for poor outcomes among bladder cancer patients is metastatic disease during follow-up. With currently available drugs, metastatic disease to other solid organs is only curable in less than 10% of patients, according to Virginia urologist Dan Theodorescu, MD, PhD.
Go to a grand rounds or medical conference and listen. What do you hear? In most discussions of patient care, clinicians relate compelling anecdotes typically beginning with “I once had a patient who…” Fill in the blank.
SAN FRANCISCO—Urinary schistosomiasis is a common infection in sub-Saharan Africa and the Mideast, and more cases could surface in the United States because of greater international travel and immigration from those regions, according to an infectious disease specialist.